Idenix Pharmaceuticals, Inc.

Other

L'université Montpellier Ii

Centre National De La Recherche Scientifique

G.d. Searle & Company

Medimmune Vaccines, Inc.

Novartis Ag

Monsanto Company

Medimmune Limited

Cnrs

Aviron

Idenix Limited

Martin L Bryant

Gilles J Gosselin

Jean-Louis Imbach

Richard A Mueller

Richard A Partis

Jean-Pierre Sommadossi

Hong Jin

Roderick Tang

Shengqiang Li

Raymond F Schinazi

Raymond A Dwek

Maureen W Myers

James M Buschow

Francis J Koszyk

Timothy Michael Block

Gary S Jacob

Frances M Platt

Gilles Gosselin

Marino Artico

Paolo La Colla

Terence D Butters

Mary L Smidt

Karen E Potts

Simon P Tucker

Gunilla B Karlsson

Simon J Davis

This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-&#x3b2;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2&#x2032;-deoxy-&#x3b2;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2&#x2032;-deoxy-&#x3b2;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2&#x2032;-deoxy-&#x3b2;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

&#x3b2;-L-2'-deoxy-nucleosides for the treatment of hepatitis B

Apparatuses and methods for facilitating reloading and resisting recoil of a firearm include an elastic member in communication with a portion of the firearm. A contact member coupled to the portion of the firearm, the elastic member, or combinations thereof, is movable between a first position in which movement of the portion of the firearm is biased by the elastic member and a second position in which movement of the portion of the firearm is generally unaffected by the elastic member. An actuator can be used to move the contact member between the first and second positions.

Systems and methods for providing firearms with lighter cocking action

An improved semiautomatic firearm is provided comprising as assembly which reduces the effort of cocking the firearm or loading a first cartridge. A spring tube contains an inner recoil spring which is employed only during cycling of the firearm when firing. For initial cocking purposes, the inner recoil spring is bypassed in favor of a lighter outer spring which is selectively engaged by the user. When the inner recoil spring is engaged, both inner and outer springs are employed without adversely affecting the recoil dynamics of the firearm.

Semiautomatic firearm having lighter cocking action

The present invention relates to compounds, compositions and methods for the treatment of a host infected with a hepatitis B virus. Specifically, compound and compositions of 3'-esters of 2&#x2032;-deoxy-&#x3b2;-L-pyrimidine nucleosides are disclosed, which can be administered either alone or in combination with other anti-hepatitis B agents. Compound and compositions of 3&#x2032;,5&#x2032;-diesters of 2&#x2032;-deoxy-&#x3b2;-L-pyrimidine nucleosides are also disclosed, which can be administered either alone or in combination with other anti-hepatitis B agents.

3'-prodrugs of 2&#x2032;-deoxy-&#x3b2;-L-nucleosides

The present invention relates to genetically engineered recombinant RS viruses and viral vectors which contain heterologous genes which for the use as vaccines. In accordance with the present invention, the recombinant RS viral vectors and viruses are engineered to contain heterologous genes, including genes of other viruses, pathogens, cellular genes, tumor antigens, or to encode combinations of genes from different strains of RSV.

Recombinant RSV virus expression systems and vaccines

This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-&#x3b2;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2&#x2032;-deoxy-&#x3b2;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2&#x2032;-deoxy-&#x3b2;-L-eythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2&#x2032;-deoxy-&#x3b2;-L-erythro pentofuranonucleoside or in combination with another anti-hepatitis B agent.

The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.

This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-&#x3b2;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2&#x2032;-deoxy-&#x3b2;-L-erythro-pentofuranonucleoside has the formula:wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2&#x2032;-deoxy-&#x3b2;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2&#x2032;-deoxy-&#x3b2;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

The present invention relates to compounds, compositions and methods for the treatment of a host infected with a hepatitis B virus. Specifically, compound and compositions of 3'-esters of 2&#x2032;-deoxy-&#x3b2;-L-nucleosides are disclosed, which can be administered either alone or in combination with other anti-hepatitis B agents. Compound and compositions of 3&#x2032;,5&#x2032;-diesters of 2&#x2032;-deoxy-&#x3b2;-L-nucleosides are disclosed, which can be administered either alone or in combination with other anti-hepatitis B agents, are also disclosed.

Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections

A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2&prime;-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof.

Methods of treating hepatitis delta virus infection with &bgr;-L-2&prime;-deoxy-nucleosides

N-Substituted glucamine compounds of formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections the compounds of formular I may be used alone, or in combinatioin with another antiviral agent selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combination of such other agents.

Glucamine salts for treating hepatitis virus infections

It has been discovered that 3&prime;-azido-2&prime;,3&prime;-dideoxyuridine (CS-87) induces a transient mutation in HIV-1 at the 70 codon (K to R, i.e., lysine to arginine) of the reverse transcriptase region of the virus. Based on this discovery, a method and composition for treating HIV is provided that includes administering CS-87 or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70 codon of the reverse transcriptase region. This invention can be practiced by referring to the published mutation patterns for known anti-HIV drugs, or by determining the mutation pattern for a new drug.

Growing community of inventors

Carlisle, MA, United States of America

Martin L Bryant